Advances in The Use of Parp Inhibitors For Brca1/2-Associated Breast Cancer: Talazoparib

Abstract excerpt

Poly-ADP-ribosyl polymerase (PARP) enzymes PARP-1 and PARP-2 recognize DNA damage and set off a cascade of cellular mechanisms required for multiple types of DNA damage repair. PARP inhibitors are small molecule mimetics of nicotinamide which bind to PARP’s catalytic domain to inhibit poly-ADP-ribosylation (PARylation) of target proteins, including PARP-1 itself. PARP inhibitors olaparib, veliparib, talazoparib,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to BRCA gene mutations in cancer
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy